CLAIMS

1. A formulation for adenoviruses comprising:

a) a recombinant adenovirus;

b) a citrate buffer;

c) hydroxypropyl-beta-cyclodextrin (HBCD);

d) a salt;

e) a non-ionic detergent;

wherein said formulation has a pH ranging between 5.5 and 6.5.

2. A formulation according to claim 1, wherein the citrate concentration is ranging between 5 mM and 30 mM.

3. A formulation according to claim 1 or 2, wherein the concentration of HBCD is ranging between 1% (w/w) to 10% (w/w).

4. A formulation according to any one of claims 1-3, wherein the salt is sodium chloride.

5. A formulation according to claim 4, wherein the sodium chloride concentration is ranging between 20 mM to about 200 mM.

6. A formulation according to any one of claims 1-5, wherein the non-ionic detergent is Polysorbate-80.

7. A formulation according to claim 6, wherein the Polysorbate-80 concentration is ranging between 0.005% (w/w) to 0.5% (w/w).

8. A formulation according to any one of claims 1-7, wherein said formulation has a pH ranging between 5.7 and 6.3, and comprises citrate at a concentration ranging between 5 and 30 mM; HBCD at a concentration ranging between 1% (w/w) and 10% (w/w); NaCl at a concentration ranging between 20 mM and 200 mM; Polysorbate-80 at a concentration ranging between 0.01% (w/w) and 0.05% (w/w).

9. A formulation according to any one of claims 1-8, wherein the formulation further comprises 2 or 4-carbon alcohol.

10. A formulation according to claim 9, wherein the 2 or 4-carbon alcohol is ethanol.

11. A formulation according to claim 10, wherein the ethanol concentration is ranging between 0.1% (w/w) to 1% (w/w).

12. A formulation according to any one of claims 9-11, wherein said formulation has a pH ranging between 5.7 and 6.3, and comprises citrate at a concentration ranging between 5 and 30 mM; HBCD at a concentration ranging between 1% (w/w) and 10% (w/w); NaCl at a concentration ranging between 20 mM and 200 mM; Polysorbate-80 at a concentration ranging between 0.01% (w/w) and 0.05% (w/w); and ethanol at a concentration ranging between 0.2% (w/w) and 0.6% (w/w).

13. A formulation according to claim 12, wherein said formulation has a pH of 6, and comprises citrate at a concentration of 20 mM; HBCD at a concentration of 5% (w/w); NaCl at a concentration of 80 mM, Polysorbate-80 at a concentration of 0.025% (w/w) and ethanol at a concentration of 0.4% (w/w).

14. A formulation according to any one of claims 10-12, wherein said formulation has a pH ranging between 5.9 and 6.2, and comprises citrate at a concentration ranging between 10 and 25 mM; HBCD at a concentration ranging between 4% (w/w) and 6% (w/w); NaCl at a concentration ranging between 70 mM and 100 mM; Polysorbate-80 at a concentration ranging between 0.018% (w/w) and 0.035% (w/w); and ethanol at a concentration ranging between 0.3% (w/w) and 0.45% (w/w).

15. A formulation according to any one of claims 1-14, wherein said formulation is a liquid formulation.

16. A formulation according to any one of claims 1-15, wherein said formulation is suitable for parenteral use.

17. A method of preserving an adenovirus which comprises preparing a formulation according to any one of claims 1-16.

18. A method of preserving an adenovirus which comprises preparing a formulation according to any one of claims 1-16 and storing said formulation at a temperature ranging between 2°C and 8°C.